Home » Surgical Implantation, Dosage Issues Raise FDA Flags Over Titan’s Anti-Opioid Drug
Surgical Implantation, Dosage Issues Raise FDA Flags Over Titan’s Anti-Opioid Drug
March 20, 2013
FDA reviewers appear satisfied with Titan Pharmaceuticals’ Probuphine’s overall safety, but worry surgically implanting the anti-opioid drug may cause adverse events similar to those that plagued Wyeth’s discontinued contraceptive Norplant. FDA reviewers also question whether adequate dose exploration has been conducted.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
21Oct